Cardiovascular management of Marfan syndrome

Israel Medical Association Journal

Volumn 10, Issue 3, 2008, Pages 182-185

  Motro, Michael ^a,b   Fisman, Enrique Z ^b   Tenenbaum, Alexander ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Ascending aorta; Beta blockade; Fibrillin 1 gene; Marfan syndrome; Prophylactic aortic root surgery

Indexed keywords

ATENOLOL; FIBRILLIN 1; METOPROLOL; PROPANOL;

AGE DISTRIBUTION; AORTA DISSECTION; ARTERY DILATATION; ARTICLE; ATHLETE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHROMOSOME 15; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; GENE MUTATION; HISTOCHEMISTRY; HUMAN; LABORATORY DIAGNOSIS; MARFAN SYNDROME; MUTATION RATE; PREECLAMPSIA; PREGNANCY;

CARDIOVASCULAR DISEASES; HUMANS; MARFAN SYNDROME;

EID: 43249101100     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Treasure T. Surgery: cardiovascular surgery for Marfan syndrome. Heart 2000;84:674-8.
2. Dietz Hc, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337-9.
3. Robinson PN, Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. J Med Genet 2000;37:9-25.
4. Pyeritz RE. Marfan syndrome and other disorders of fibrillin. In: Rimoin DL, Conner JM, Pyeritz RE, Korf B, eds. Principles and Practice of Medical Genetics. 4th edn. Edinburgh: Churchill Livingstone; 2002:3977-4020.
5. DePaepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-26.
6. Dietz HC, Pyeritz RE. Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. Hum Mol Genet 1995;4:1799-809.
7. Loeys B, Nuytinck L, Delvaux I, et al. Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med 2001;161:244-54.
8. Thoene JG. Marfan syndrome. In: Physician's Guide to Rare Diseases. 2nd ed. Montvale, NJ: Dowden Publishing Company, Inc, 1995.
9. Liu W, Schrijver I, Brenn T, Furthmayr H, Francke U. Multi-exon deletions of the FBN1 gene in Marfan syndrome. Med Genet 2001; 2:11.
10. Wang M, Price CE, Han J, et al. Recurrent mis-splicing of fibrillin exon 32 in two patients with neonatal Marfan syndrome. Hum Mol Genet 1995;4:607-13.
11. Tuncbilek E, Alanay Y. Congenital contractural arachnodactyly (Beals syndrome). Orphanet J Rare Dis 2006;1:20.
12. Dean JCS. Management of Marfan syndrome. Heart 2002;88:97-103.
13. Lipscomb KJ, Clayton-Smith I, Harris R. Evolving phenotype of Marfan's syndrome. Arch Dis Child 1997;76:41-6.
14. Groenink M, Lohuis TA, Tijssen JG, et al. Survival and complication free survival in Marfan's syndrome: implications of current guidelines. Heart 1999:82:499-504.
15. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term β-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330;1335-41.
16. Salim MA, Alpert BS, Ward JC, et al. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. Am J Cardiol 1994;74:629-33.
17. Haouzi A, Berglund H, Pelikan PC, et al. Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. Am Heart J 1997;133:60-3.
18. Groenink M, de Roos A, Mulder BJ, et al. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998;82:203-8.
19. Yetman AT, Bornemeier RA, McCrindle BW. Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death? J Am Coll Cardiol 2003:41:329-32.
20. Tierney ESS, Feingold B, Printz BF, et al. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 2007;150:77-82.
21. Nagashima H, Sakomura Y, Aoka Y, et al. Angiotensin II type 2 receptor mediates muscle cell apoptosis in cystic medical degeneration associated with Marfan's syndrome. Circulation 2001; 104(Suppl I):I-282-7.
22. Lind J, Wallenburg HC. Marfan syndrome and pregnancy: a retrospective study in a Dutch population. Eur J Obstet Gynaecol Reprod Biol 2001;98:28-35.
23. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. Task force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 2005; 45:1340-5.
24. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 2006;48:1-148.
25. Finkbohner R, Johnston D, Crawford S, et al. Marfan syndrome: long-term survival and complications after aortic aneurysm repair. Circulation 1995;91:728-33.